stoxline Quote Chart Rank Option Currency Glossary
  
ACADIA Pharmaceuticals Inc. (ACAD)
14.35  -0.03 (-0.21%)    04-22 16:00
Open: 14.6
High: 14.785
Volume: 1,744,432
  
Pre. Close: 14.38
Low: 14.08
Market Cap: 2,393(M)
Technical analysis
2025-04-22 3:45:09 PM
Short term     
Mid term     
Targets 6-month :  18.68 1-year :  20.55
Resists First :  15.99 Second :  17.6
Pivot price 14.97
Supports First :  13.39 Second :  11.14
MAs MA(5) :  14.59 MA(20) :  15.48
MA(100) :  17.42 MA(250) :  16.6
MACD MACD :  -0.8 Signal :  -0.8
%K %D K(14,3) :  29.9 D(3) :  32
RSI RSI(14): 35.1
52-week High :  20.68 Low :  13.39
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ACAD ] has closed above bottom band by 28.3%. Bollinger Bands are 20.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 14.76 - 14.84 14.84 - 14.9
Low: 14.01 - 14.09 14.09 - 14.15
Close: 14.27 - 14.39 14.39 - 14.49
Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Headline News

Mon, 21 Apr 2025
Acadia Pharmaceuticals (ACAD) Price Target Lowered by BofA Before Q1 Earnings | ACAD Stock News - GuruFocus

Sun, 13 Apr 2025
Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? - Yahoo Finance

Fri, 11 Apr 2025
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Fri, 11 Apr 2025
Neuroscience Leader Acadia Expands Team with Major Equity Compensation Package - Stock Titan

Tue, 25 Mar 2025
Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts - Yahoo Finance

Mon, 17 Mar 2025
Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 167 (M)
Shares Float 114 (M)
Held by Insiders 0.4 (%)
Held by Institutions 100.3 (%)
Shares Short 14,430 (K)
Shares Short P.Month 15,210 (K)
Stock Financials
EPS 1.36
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.4
Profit Margin 23.6 %
Operating Margin 2.6 %
Return on Assets (ttm) 5.4 %
Return on Equity (ttm) 38.8 %
Qtrly Rev. Growth 12.3 %
Gross Profit (p.s.) 3.43
Sales Per Share 5.74
EBITDA (p.s.) 0.6
Qtrly Earnings Growth 213.3 %
Operating Cash Flow 158 (M)
Levered Free Cash Flow 270 (M)
Stock Valuations
PE Ratio 10.52
PEG Ratio 0
Price to Book value 3.25
Price to Sales 2.49
Price to Cash Flow 15.13
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android